KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.

M Li, Y Pan, G Jiang, Q Wang, G Wu, W Feng, C Zhou, Q Bu, S Ma, H Jiang, J Chen, H Yu, M Yu, Q Liu, X Hou, L Chen

ESMO Open 10(12) 105908

PMID41270700
PMCIDPMC12670085
DOI10.1016/j.esmoop.2025.105908
发表日期2025-11-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: There is a lack of prospective randomized controlled trials of antiangiogenic therapy in patients with brain metastases. We conducted this phase III, randomized, multicenter study (BAP BRAIN) to evaluate the intracranial efficacy and safety of bevacizumab plus chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) and brain metastases, and provide evidence for this previously unexplored subgroup. PATIENTS AND METHODS: Treatment-naïve, non-squamous NSCLC patients with confirmed brain metastases and without sensitizing epidermal growth factor receptor or anaplastic lymphoma kinase mutations were screened from 11 centers in China. The eligible patients were randomly assigned (1 : 1) to receive bevacizumab plus pemetrexed-platinum or pemetrexed-platinum for four to six cycles, followed by bevacizumab plus pemetrexed or pemetrexed maintenance until disease progression, unacceptable toxicity, or death. The primary endpoint was intracranial progression-free survival (iPFS), and secondary endpoints included PFS, overall survival (OS), intracranial objective response rate (iORR), systemic ORR, and safety. RESULTS: A total of 160 patients were eligible and underwent randomization, and 153 patients received at least one dose of drug and were included in the full analysis set. After a median follow-up of 16.8 months, the median iPFS was 11.07 months in the bevacizumab plus pemetrexed-platinum group versus 7.37 months in the pemetrexed-platinum group [hazard ratio (HR) 0.494, P < 0.001]. Similarly, the median systemic PFS was significantly longer with bevacizumab plus pemetrexed-platinum than with pemetrexed-platinum alone (8.77 months versus 5.23 months, HR 0.540, P < 0.001). The bevacizumab plus pemetrexed-platinum group had better iORR (69.6% versus 32.4%) and ORR (58.2% versus 27.0%) and remission rate of cerebral edema (88.9% versus 41.9%) than the pemetrexed-platinum group. At data cut-off, the median OS was 28.07 months in the bevacizumab plus pemetrexed-platinum group versus 18.53 months in the pemetrexed-platinum group (HR 0.752, P = 0.162). There was no grade ≥3 intracranial hemorrhage, and most of the adverse events were manageable. CONCLUSIONS: This study demonstrated encouraging intracranial efficacy and acceptable safety of bevacizumab plus chemotherapy in patients with non-squamous NSCLC and brain metastases in the first-line setting.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2 Kaplan–Meier estimates of intracranial PFS (A), systemic PFS (B), and OS (C) in FAS. P value was calculated using stratified log-rank test. HR and corresponding 95% CI were evaluated using Cox proportional hazards regression model. FAS, full analysis set; iPFS, intracranial PFS; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.

A

intracranial PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

systemic PFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Patient flowchart.
非 KM Figure